Skip to content

Increasing Physical Activity in COPD Through Rhythmically Enhanced Music

Increasing Physical Activity in COPD Through Rhythmically Enhanced Music

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03655028
Enrollment
93
Registered
2018-08-31
Start date
2018-10-01
Completion date
2023-11-14
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Patients and Patients Recovering From COVID19

Keywords

COPD, Exercise, Rehabilitation

Brief summary

The VA cares for nearly one million Veterans with COPD at a cost of more than $5.5 billion annually. COPD profoundly impairs quality of life as it limits ability to work, to maintain physical exertion and to engage in social activities. Hospital-based rehab can decrease the need for inpatient and outpatient medical care and can improve exercise capacity, quality of life and, possibly, decrease mortality. Unfortunately, access to hospital-based VA rehab is insufficient and, over time, the few Veterans who attend experience progressive loss of functional gains. The investigators reason that the proposed home-based exercise program augmented by patient-tailored, RAS-enhanced music will overcome the many limitations of hospital-based rehab. Through this innovative program, the investigators expect to enhance the benefits of rehab and better maintain them over time. The easy applicability of this innovative, accessible and economical program has the potential to modify the spiraling pattern of increasing disability and reduce health-care cost and mortality in Veterans with COPD. In 2021, the investigators obtained an 'Administrative Project Modification' to the parent COPD study in which they will include patients recovering from prolonged COVID19 hospitalization. Specifically, the investigators will use the novel RAS-enhanced music exercise program developed for the parent grant in patients recovering from COVID19. The main goal of the modified proposal for COVID19 patients will be to compare the efficacy of a 12-week, home-based exercise program augmented by RAS-therapeutic music and strength training to 12-weeks usual care and strength training in patients recovering from COVID 19.

Detailed description

Rationale: In COPD, hospital-based pulmonary rehabilitation can improve symptoms, functional status, and quality of life and decrease unscheduled physician visits, emergency room visits, hospitalizations, and possibly, mortality. Despite the well documented efficacy, hospital-based rehab remains inadequate due to insufficient access, acceptance and sustainability. This has triggered a growing interest in home-based rehab programs. Patients enrolled in home-based programs, however, may exercise at low intensities to avoid dyspnea/fatigue, limiting the potential benefits of exercise training. Accordingly, it is essential to develop innovative home-based programs that decrease exercise-induced dyspnea and fatigue while ensuring sufficient exercise intensity to produce sustainable physiologic benefit. Recent data suggest that rhythmically auditory stimulation (RAS) using music may constitute such an innovative strategy. Music can diminish exercise-induced dyspnea/fatigue allowing patients to tolerate more challenging physical activity and obtain a greater benefit from rehab. Music also can induce entrainment of motor responses such as walking. The investigators thus plan to capitalize on both the sensorimotor coupling of gait with RAS-enhanced music and the mitigating effect of music over exercise-induced dyspnea/fatigue. Specifically, the investigators propose to compare the efficacy of a 12-week, home-based exercise program augmented by patient-tailored, RAS-enhanced music to a 12-week traditional home-based exercise program in patients with COPD. Hypothesis: (H1) Compared to patients randomized to a home-based, exercise program without music (control group), patients randomized to a home-based, exercise program augmented with RAS-enhanced music (intervention group) will demonstrate (H1a, primary hypothesis) greater increase in 6-minute walk distance, (H1b) greater increase in walking time on a constant-load treadmill test protocol, (H1c) reduced dyspnea during a constant-load treadmill test protocol, and (H1d) greater increases in health-related quality of life. In addition (H2), they will accumulate greater volume of physical activity (actigraphy) and (H3) will better sustain these benefits over time. Lastly (Explorative Objective), the investigators will assess the mechanistic impact physiological and psychological phenotype and clinical factors on responsiveness to rehabilitation (duration constant-load treadmill test) achieved with and without concurrent use of RAS-music. Methods: The proposed study is a randomized, controlled clinical trial in which 170 patients will be randomized into a home-based, exercise program without music or a home-based exercise program augmented with RAS-enhanced music. Patients will receive 12-weeks of home-based training per group assignment (at least three times weekly) followed by 12-weeks of follow-up to assess the sustainability of the investigators' novel intervention. Testing will be carried out at baseline and at 6, 12 and 24 weeks. Testing will include pulmonary function test, 6-minute walk tests, constant-load treadmill test, physical activity quantification, measurements of dyspnea, quality of life, and objective quantification of quadriceps dimensions (ultrasonography) and strength/fatigue (magnetic stimulation of the femoral nerve). Analysis: In the principal analysis of the primary outcome measure (6-minute walk distance) the investigators will use a mixed-model analysis that includes, treatment, time and treatment-by-time interaction terms. This model will automatically account for missing data-where missing at random is assumed. The investigators will conduct a sensitivity analysis based on the results of the mixed model analysis to determine which other assumptions regarding missing data might produce different results. One component of the sensitivity analysis will include adjustment for baseline demographic and health covariates. A linear regression model and a mixed model ANOVA will be used to assess the impact of clinical confounders (Explorative Objective). Scientific contribution: These data will provide a solid foundation to determine the physiologic impact of the rehab strategy. This innovative, practical and economical pulmonary rehabilitation strategy has the potential to create a paradigm shift in the care of the many Veterans with COPD who have no access to pulmonary rehabilitation. The above-described protocol will be also tested in patients recovering form COVID19. The investigators reason that the proposed innovative, practical, safe and economical program has the potential to create a paradigm shift in the care of the many veterans who were hospitalized with COVID19 and who have no access to physical rehabilitation. Please note: Due to the COVID-19 pandemic, constant load treadmill testing could not be completed as was originally proposed. There was concern that COVID-19 could be transmitted due to increased exposure to increased saliva associated with testing. Therefore, the objectives using constant load testing will not be reported. The exploratory objective was based on the constant workload treadmill test so that is not reported. Additionally, again due to the COVID-19 pandemic, 6-week testing was not completed after the pandemic due to the increased risk of transmission (n.b., 6-week data were not included in the outcomes and was to be used for analysis of the primary objective; as such, the analysis of the primary objective was changed to ANCOVA from what was in the protocol). The protocol attached here is the last approved IRB protocol and includes both patients with COPD and COVID. Only data on patients with COPD are reported here. The two groups of patients were two different populations and it does not make theoretical sense to combine the data at this point. Text concerning COVID are in gray.

Interventions

BEHAVIORALrhythmically auditory stimulation enhanced music

Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program

BEHAVIORALcontrol

Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Both investigator and outcome assessor will be blinded to patient allocation

Intervention model description

Randomized controlled trial in which COPD patients in the intervention group and COVID19 patient in the intervention group will undergo a home-based, exercise program augmented with RAS-enhanced music while COPD patients in the control group and COVID19 patients in the control group will undergo a home-based, exercise program without music. Outcomes of the home-based exercise program with music will be compared to the outcomes of home-based exercise alone. Outcomes are listed below.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

COPD patients: * =\< 40 yr. of age * FEV1 =\< 70% * FEV1/FVC \<70% * Mean SpO2 88% at peak exercise (with or without oxygen supplementation) COVID19 patients * \>=18 yrs. of age * Previous hospital and/or emergency room visit for laboratory-confirmed COVID-19 diagnosis. * Able to walk independently * Mean SpO2 88% at peak exercise (with or without oxygen supplementation) * Ability to hear music

Exclusion criteria

COPD patients: * Respiratory infection/COPD exacerbation within the previous four weeks * Exercise-limiting heart disease * Congestive heart failure - i.e., New York Heart Association Class III or IV * Positive stress test or other indicators of heart disease or complaints of angina during the stress test * Exercise-limiting peripheral arterial disease * Stops walking due to intermittent claudication * Stops exercise for arthritic pain in knee or hips * Inability to walk on the treadmill * Any unforeseen illness or disability that would preclude exercise testing or training * Participation in a formal exercise program within the previous 12-weeks COVID patients: * Able to walk more than 550 meters during a standard 6-minute walk test * Exercise limiting heart disease * Complaints of angina during the 6- minute walk distance tests or other indicators of exercise-limiting heart disease * Congestive heart failure (New York Heart Association Class III or IV) * Exercise-limiting peripheral arterial disease (stops exercise due to intermittent claudication) * Stops exercise due to arthritic pain in the knee or hips (self-report) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Six-minute Walk Distance12 weeksPatients will be instructed to walk as fast as they can without running for six minutes. The test will be conducted according to ATS standards. Distance will be recorded in meters walked. Outcomes will be compared between the intervention groups.

Secondary

MeasureTime frameDescription
Quality of Life Physical Function12 weeksmeasured by the Short Form-36 Physical component score. Scores range from 0-100 (higher scores are better).
Volume of Daily Physical Activity12 weeksVolume of daily physical activity over a seven day period will be recorded using a triaxial accelerometer worn on the hip (actigraph). Volume of physical activity will be compared between the intervention group and the control group.
Six-minute Walk Distance24 weeksTo determine whether, 24-weeks after randomization, gains in 6-minute walk distance and perceived functional improvements will be sustained to a greater extent in the rhythmic auditory stimulation enhanced music group than in the control group the six-minutes walk test will be repeated 24-weeks after randomization. During the six-minute walk test patients will be instructed to walk as fast as they can without running for six minutes. The test will be conducted according to ATS standards. Distance will be recorded in meters walked. Outcomes will be compared between the two groups.
Quality of Life Mental Health12-weeksQuality of Life measured by Short Form-36 Mental Component Scale (range=0-100; higher score is better)

Other

MeasureTime frameDescription
Adherence to Training Sessions Protocol12 weeksnumber of walking exercise sessions completed

Countries

United States

Participant flow

Recruitment details

93 participants met the criteria and were randomized into the study.

Participants by arm

ArmCount
Intervention
Music plus 12-week walking program
46
Control
12-week walking program only
47
Total93

Withdrawals & dropouts

PeriodReasonFG000FG001
12-weeks Follow upDeath10
12-weeks Follow upLost to Follow-up44
12-weeks Follow upPhysician Decision33
12-weeks Follow upWithdrawal by Subject20
24-weeksDeath01
24-weeksLost to Follow-up11

Baseline characteristics

CharacteristicControlInterventionTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
43 Participants36 Participants79 Participants
Age, Categorical
Between 18 and 65 years
4 Participants10 Participants14 Participants
Age, Continuous73 years
STANDARD_DEVIATION 6
69 years
STANDARD_DEVIATION 6
71 years
STANDARD_DEVIATION 6
Daily step count2750 steps per day
STANDARD_DEVIATION 1648
3308 steps per day
STANDARD_DEVIATION 1346
3008 steps per day
STANDARD_DEVIATION 1532
Dyspnea3.5 units on scale
STANDARD_DEVIATION 1.6
3.4 units on scale
STANDARD_DEVIATION 1.9
3.5 units on scale
STANDARD_DEVIATION 1.7
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants1 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
45 Participants45 Participants90 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
FEV11.39 Liters
STANDARD_DEVIATION 0.46
1.49 Liters
STANDARD_DEVIATION 0.51
1.44 Liters
STANDARD_DEVIATION 0.49
FEV1/FVC47 percent
STANDARD_DEVIATION 13
51 percent
STANDARD_DEVIATION 11
49 percent
STANDARD_DEVIATION 12
FEV1 percent predicted45 percent predicted
STANDARD_DEVIATION 15
48 percent predicted
STANDARD_DEVIATION 13
47 percent predicted
STANDARD_DEVIATION 14
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
9 Participants16 Participants25 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
38 Participants30 Participants68 Participants
Region of Enrollment
United States
47 Participants46 Participants93 Participants
Sex: Female, Male
Female
0 Participants7 Participants7 Participants
Sex: Female, Male
Male
47 Participants39 Participants86 Participants
Six minute walk distance403 meters
STANDARD_DEVIATION 98
433 meters
STANDARD_DEVIATION 81
418 meters
STANDARD_DEVIATION 91

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 461 / 47
other
Total, other adverse events
0 / 460 / 47
serious
Total, serious adverse events
3 / 464 / 47

Outcome results

Primary

Six-minute Walk Distance

Patients will be instructed to walk as fast as they can without running for six minutes. The test will be conducted according to ATS standards. Distance will be recorded in meters walked. Outcomes will be compared between the intervention groups.

Time frame: 12 weeks

Population: Participants assigned to each group who completed 12-week testing

ArmMeasureValue (MEAN)Dispersion
InterventionSix-minute Walk Distance452 metersStandard Deviation 79
ControlSix-minute Walk Distance429 metersStandard Deviation 105
p-value: 0.85ANCOVA
Secondary

Quality of Life Mental Health

Quality of Life measured by Short Form-36 Mental Component Scale (range=0-100; higher score is better)

Time frame: 12-weeks

Population: some subjects did not complete the questionnaires

ArmMeasureValue (MEAN)Dispersion
InterventionQuality of Life Mental Health42.8 score on a scaleStandard Deviation 6.1
ControlQuality of Life Mental Health42.3 score on a scaleStandard Deviation 6.6
p-value: 0.85ANCOVA
Secondary

Quality of Life Physical Function

measured by the Short Form-36 Physical component score. Scores range from 0-100 (higher scores are better).

Time frame: 12 weeks

Population: numbers of subjects are inconsistent because subjects did not complete the questionnaires

ArmMeasureValue (MEAN)Dispersion
InterventionQuality of Life Physical Function40.4 score on a scaleStandard Deviation 6
ControlQuality of Life Physical Function38.7 score on a scaleStandard Deviation 7.3
p-value: 0.26ANCOVA
Secondary

Six-minute Walk Distance

To determine whether, 24-weeks after randomization, gains in 6-minute walk distance and perceived functional improvements will be sustained to a greater extent in the rhythmic auditory stimulation enhanced music group than in the control group the six-minutes walk test will be repeated 24-weeks after randomization. During the six-minute walk test patients will be instructed to walk as fast as they can without running for six minutes. The test will be conducted according to ATS standards. Distance will be recorded in meters walked. Outcomes will be compared between the two groups.

Time frame: 24 weeks

ArmMeasureValue (MEAN)Dispersion
InterventionSix-minute Walk Distance444 metersStandard Deviation 82
ControlSix-minute Walk Distance439 metersStandard Deviation 107
p-value: 0.106ANCOVA
Secondary

Volume of Daily Physical Activity

Volume of daily physical activity over a seven day period will be recorded using a triaxial accelerometer worn on the hip (actigraph). Volume of physical activity will be compared between the intervention group and the control group.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
InterventionVolume of Daily Physical Activity3930 steps per dayStandard Deviation 2551
ControlVolume of Daily Physical Activity3738 steps per dayStandard Deviation 2566
p-value: 0.307ANCOVA
Other Pre-specified

Adherence to Training Sessions Protocol

number of walking exercise sessions completed

Time frame: 12 weeks

Population: total number of sessions completed

ArmMeasureValue (MEAN)Dispersion
InterventionAdherence to Training Sessions Protocol25.6 number of training sessions completedStandard Deviation 10.7
ControlAdherence to Training Sessions Protocol19.7 number of training sessions completedStandard Deviation 12.8
p-value: 0.025t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026